Versartis’ research and development efforts are focused on orphan endocrine diseases for which improved treatment approaches are needed.

The company’s lead candidate, somavaratan (VRS-317), is a novel, long-acting form of recombinant human growth hormone. Somavaratan is currently in Phase 3 clinical trials for the treatment of pediatric growth hormone deficiency (GHD) and a Phase 2 clinical trial for the treatment of adult GHD.

Current and future research efforts are focused on areas of unmet patient need in endocrine diseases. Contact us directly to discuss partnership opportunities.